Differential Effects of Ursodeoxycholic Acid and Ursocholic Acid on the Formation of Biliary Cholesterol Crystals in Mice
Overview
Authors
Affiliations
The preventive effect of 3 alpha, 7 beta, 12 alpha-trihydroxy-5 beta-cholanoic acid (ursocholic acid) and ursodeoxycholic acid on the formation of biliary cholesterol crystals was studied in mice. Cholesterol crystals developed with 80% incidence after feeding for five weeks a lithogenic diet containing 0.5% cholesterol and 0.25% sodium cholate. When 0.25% ursocholic acid or ursodeoxycholic acid was added to the lithogenic diet, the incidence as well as the grade (severity) of the gallstones were reduced. Plasma and liver cholesterol levels were decreased by ursodeoxycholic acid but not by ursocholic acid. Gallbladder cholesterol and phospholipid levels were decreased by both bile acids. The biliary bile acid level was decreased by ursocholic acid but not by ursodeoxycholic acid. After feeding ursocholic acid, its level in the bile was about 25% and the levels of cholic acid and beta-muricholic acid decreased. Fecal sterol excretion was not changed by ursocholic acid, but was increased by ursodeoxycholic acid. After feeding ursocholic acid, fecal excretion of deoxycholic acid, cholic acid, and ursocholic acid increased. No differences were found between mice, with or without gallstones, in plasma and liver cholesterol levels, biliary phospholipid and bile acid levels, fecal sterol and bile acid levels, and biliary and fecal bile acid composition. The results suggest that the lower incidence of crystal formation after treatment with ursocholic acid is probably by a different mechanism than with ursodeoxycholic acid. In the mouse model, ursodeoxycholic acid exerts its effect at least partially, by decreasing cholesterol absorption. Ursocholic acid is well absorbed and excreted into bile and transformed into deoxycholic acid by the intestinal microflora in mice.
Rumen microbiome-driven insight into bile acid metabolism and host metabolic regulation.
Zhang B, Jiang X, Yu Y, Cui Y, Wang W, Luo H ISME J. 2024; 18(1).
PMID: 38836500 PMC: 11193847. DOI: 10.1093/ismejo/wrae098.
Orozco-Aguilar J, Tacchi F, Aguirre F, Valero-Breton M, Castro-Sepulveda M, Simon F Biol Res. 2023; 56(1):28.
PMID: 37237400 PMC: 10224307. DOI: 10.1186/s40659-023-00431-8.
Fujita K, Iguchi Y, Une M, Watanabe S Lipids. 2017; 52(4):335-344.
PMID: 28315136 DOI: 10.1007/s11745-017-4242-5.
Therapy of gallstone disease: What it was, what it is, what it will be.
Portincasa P, Di Ciaula A, Bonfrate L, Wang D World J Gastrointest Pharmacol Ther. 2012; 3(2):7-20.
PMID: 22577615 PMC: 3348960. DOI: 10.4292/wjgpt.v3.i2.7.
Targets for current pharmacologic therapy in cholesterol gallstone disease.
Di Ciaula A, Wang D, Wang H, Bonfrate L, Portincasa P Gastroenterol Clin North Am. 2010; 39(2):245-64, viii-ix.
PMID: 20478485 PMC: 2915454. DOI: 10.1016/j.gtc.2010.02.005.